Irinotecan and Bevacizumab for Recurrent Ovarian Cancer

Part of paid clinical trials in New York, New York.

Sponsor
NYU Langone Health
Study ID
NCT01091259
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of the study is to evaluate the efficacy and toxicity of irinotecan in the treatment of women with recurrent epithelial ovarian cancer or primary peritoneal cancer when combined with bevacizumab.

Key Dates

Start date
Mar 31, 2010
Status verified
Oct 2015
Primary completion
Feb 28, 2014
Completion
May 31, 2015

Study Design

Enrollment
29 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Irinotecan with Bevacizumab
    Irinotecan is administered every 3 weeks at a dose of 175 mg/m\^2, bevacizumab is administered at 15 mg/kg every 3 weeks. Irinotecan is administered before bevacizumab. Patients will continue on therapy until evidence of disease progression, or until development of adverse events that prevent further treatment, or if the patients wishes to discontinue therapy.

Primary Outcome Measure

Progression Free Survival (PFS) Rate at 6 Months [ Time Frame: 6 months from the start of treatment ]

Locations (2)

FacilityCityStateZIPSite coordinators
Bellevue Hospital Center (NYU Langone Medical Center affiliate)New YorkNew York10016-
New York University Clinical Cancer CenterNew YorkNew York10016-

Find similar trials in New York, NY

By condition
Ovarian cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
Bellevue Hospital Center (NYU Langone Medical Center affiliate)· New York, NYNew York University Clinical Cancer Center· New York, NY

Related Studies